Concepedia

Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy

Michael Haas, Volker Heinemann, Frank Kullmann, Rüdiger P. Laubender, Christina Klose, Christiane J. Bruns, Stefan Holdenrieder, Dominik Paul Modest, Christoph Schulz, Stefan Boeck

Journal of Cancer Research and Clinical Oncology · 2013 · 140 citations · 16 references

DOIFull text

Open access

Concepts

References

16

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine · 2011 · 7.8K citations · Full text

, , +13

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Malcolm J. Moore, David Goldstein, John Hamm et al. · Journal of Clinical Oncology · 2007 · 3.9K citations

, , +17

REporting recommendations for tumour MARKer prognostic studies (REMARK)

Lisa M. McShane, Douglas G. Altman, Willi Sauerbrei et al. · British Journal of Cancer · 2005 · 1.4K citations · Full text

, , +10

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

Eric Van Cutsem, Walter L. Vervenne, Jaafar Bennouna et al. · Journal of Clinical Oncology · 2009 · 643 citations · Full text

, , +12

Marimastat as First-Line Therapy for Patients With Unresectable Pancreatic Cancer: A Randomized Trial

Simon R. Bramhall, Alexander S. Rosemurgy, Peter de Nully Brown et al. · Journal of Clinical Oncology · 2001 · 434 citations

, , +11